Roivant Sciences Ltd. has filed an amendment to its previous 8-K report, detailing a Settlement Agreement with Moderna, Inc. The original report, filed on March 3, 2026, disclosed the entry into this agreement to resolve patent infringement litigation concerning Moderna's use of Genevant/Arbutus' lipid nanoparticle delivery technology in its vaccines. The amendment serves to include the full text of the Settlement Agreement as Exhibit 10.1, which was referenced in the original filing. The Settlement Agreement aims to address all patent infringement claims between the parties, specifically related to the SPIKEVAX COVID-19 vaccine. As part of the agreement, Moderna will make a noncontingent lump sum payment of $950 million to Genevant and Arbutus, with additional contingent payments based on future legal outcomes. This development is expected to have a small positive effect on Roivant's stock price, as it clarifies ongoing legal uncertainties and financial obligations. The filing indicates that Roivant remains committed to its strategic partnerships and operational execution in the biopharmaceutical sector, while also navigating complex legal landscapes.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.